CN103608026B - 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法 - Google Patents

肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法 Download PDF

Info

Publication number
CN103608026B
CN103608026B CN201280029277.6A CN201280029277A CN103608026B CN 103608026 B CN103608026 B CN 103608026B CN 201280029277 A CN201280029277 A CN 201280029277A CN 103608026 B CN103608026 B CN 103608026B
Authority
CN
China
Prior art keywords
hours
peptide
minutes
ip3r3
ebin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280029277.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103608026A (zh
Inventor
Y.A.科马罗娃
U.萨基布
S.M.沃格尔
A.B.马利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Priority to CN201610552695.3A priority Critical patent/CN106188232B/zh
Publication of CN103608026A publication Critical patent/CN103608026A/zh
Application granted granted Critical
Publication of CN103608026B publication Critical patent/CN103608026B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280029277.6A 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法 Active CN103608026B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610552695.3A CN106188232B (zh) 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
PCT/US2012/042118 WO2012174028A2 (en) 2011-06-13 2012-06-13 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610552695.3A Division CN106188232B (zh) 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Publications (2)

Publication Number Publication Date
CN103608026A CN103608026A (zh) 2014-02-26
CN103608026B true CN103608026B (zh) 2016-08-24

Family

ID=47357694

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280029277.6A Active CN103608026B (zh) 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法
CN201610552695.3A Active CN106188232B (zh) 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610552695.3A Active CN106188232B (zh) 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Country Status (15)

Country Link
US (2) US9248198B2 (enExample)
EP (1) EP2717897B1 (enExample)
JP (1) JP6042425B2 (enExample)
KR (1) KR102042015B1 (enExample)
CN (2) CN103608026B (enExample)
AU (1) AU2012271781C1 (enExample)
BR (1) BR112013032108B1 (enExample)
CA (1) CA2838662C (enExample)
DK (1) DK2717897T3 (enExample)
ES (1) ES2633343T3 (enExample)
IL (1) IL229771B (enExample)
MX (1) MX349146B (enExample)
PL (1) PL2717897T3 (enExample)
WO (1) WO2012174028A2 (enExample)
ZA (1) ZA201309161B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188232A (zh) * 2011-06-13 2016-12-07 伊利诺伊大学受托管理委员会 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427549B (zh) * 2015-03-02 2022-01-11 伊利诺伊大学受托管理委员会 用于抑制血管生成的肽
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903145A2 (en) * 1997-04-30 1999-03-24 Eli Lilly And Company Pharmaceutical composition for skin disorders
CN1890218A (zh) * 2003-12-03 2007-01-03 西托匹亚研究有限公司 微管蛋白抑制剂
US20080021036A1 (en) * 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US7368430B2 (en) * 2003-11-06 2008-05-06 Research Development Foundation Selective inhibitors of nuclear factor-κB activation and uses thereof
AU2006292203A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
KR101399175B1 (ko) * 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 항염증성 및 항알레르기성 시클릭 펩티드
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903145A2 (en) * 1997-04-30 1999-03-24 Eli Lilly And Company Pharmaceutical composition for skin disorders
CN1890218A (zh) * 2003-12-03 2007-01-03 西托匹亚研究有限公司 微管蛋白抑制剂
US20080021036A1 (en) * 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EB1 and EB3 Control CLIP Dissociation from the Ends of Growing Microtubules;Yulia Komarova等;《Molecular Biology of the Cell》;20051130;第16卷;5334-5345 *
Mammalian end binding proteins control persistent microtubule growth;Yulia Komarova等;《The Journal Of Cell Biology》;20090302;第184卷(第5期);691-706 *
Microtubule-associated protein EB3 regulates calcium signaling and facilitates increase in endothelial permeability;Yulia A Komarova等;《The FASEB Journal》;20110430;第25卷;摘要 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106188232A (zh) * 2011-06-13 2016-12-07 伊利诺伊大学受托管理委员会 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法
CN106188232B (zh) * 2011-06-13 2020-01-07 伊利诺伊大学受托管理委员会 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法

Also Published As

Publication number Publication date
MX349146B (es) 2017-07-14
ES2633343T3 (es) 2017-09-20
US9248198B2 (en) 2016-02-02
IL229771B (en) 2019-07-31
US8912139B2 (en) 2014-12-16
WO2012174028A3 (en) 2013-02-21
DK2717897T3 (en) 2017-07-17
EP2717897B1 (en) 2017-04-19
MX2013014650A (es) 2014-01-24
EP2717897A4 (en) 2015-01-07
BR112013032108A2 (pt) 2016-11-22
EP2717897A2 (en) 2014-04-16
US20140213505A1 (en) 2014-07-31
JP6042425B2 (ja) 2016-12-14
CN106188232B (zh) 2020-01-07
PL2717897T3 (pl) 2017-09-29
CA2838662A1 (en) 2012-12-20
AU2012271781B2 (en) 2017-02-16
CN103608026A (zh) 2014-02-26
CN106188232A (zh) 2016-12-07
WO2012174028A2 (en) 2012-12-20
ZA201309161B (en) 2015-03-25
AU2012271781A1 (en) 2014-01-09
KR102042015B1 (ko) 2019-11-07
US20140155314A1 (en) 2014-06-05
BR112013032108B1 (pt) 2021-10-26
KR20140056185A (ko) 2014-05-09
CA2838662C (en) 2018-07-24
AU2012271781C1 (en) 2017-09-21
JP2014518211A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
ES2637687T3 (es) Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
CN103608026B (zh) 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法
KR20210076190A (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
ES2958662T3 (es) Tratamiento de cardiopatía por inhibición de la acción de la proteína de anclaje a la cinasa A del músculo (mAKAP)
WO2019118779A2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK1248123A1 (zh) 用於治疗脓毒症的半通道胞外域特异性药剂
KR20170122762A (ko) 혈관신생 억제용 펩타이드
WO2008072781A1 (ja) 哺乳動物における記憶障害の抑制又は治療方法
CN106459168A (zh) 强心性类固醇拮抗剂和相关方法
Torabi et al. Ibrutinib reduces neutrophil infiltration, preserves neural tissue and enhances locomotor recovery in mouse contusion model of spinal cord injury
US20210347821A1 (en) Inhibitors of pick1 and uses thereof
Wang et al. Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis
ES2313029T3 (es) Metodo para evaluar la actividad de fosforilacion de lkb1.
US20130345143A1 (en) MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
CA3235623A1 (en) Recombinant polypeptide for disrupting interaction of eag2 and kvs2 and therapeutic applications thereof in cancer treatment
Li et al. Acid-sensing ion channel 3 overexpression in incisions regulated by nerve growth factor participates in postoperative nociception in rats
CN110520144A (zh) 肽激酶抑制剂及其使用方法
KR101410417B1 (ko) 혈액내의 엔도칸 측정 방법
Vannini et al. CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo. Toxins 2021, 13, 194
US10125183B2 (en) Decoy peptides inhibiting binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1
Atwell Targeting Sorting Nexins to Treat ErbB Dependent Breast Cancer
Bitler Determining the Role of Muc1 and Beta-catenin on the Epidermal Growth Factor Receptor Signaling and Localization in Breast Cancer
WO2012112869A2 (en) Targeted cancer therapy using ets transcriptional inhibitors
Begley Therapeutic in vivo applications for PKC-modulating intracellularly-acting peptides
HK1175102B (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various cardiovascular diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant